Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
DGX US​

Quest Diagnostics Inc(DGX US)

$241.89-1.390.57%Ext:$235.80-6.092.52%(Market Closed · 00:00:03 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Quest Diagnostics Inc — Company Profile

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UN
Headquarters
NJ, US

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Location
NJ, US
Employees0
Sector
Health Care
Industry
Health Care Equipment & Supplies

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(2.4K)

Expand
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 4Statement of changes in beneficial ownership23 Oct
  • 10-QQ3ended 30 Sept 202623 Oct
  • 8-KOther Events22 Oct
  • 8-KResults of Operations and Financial Condition22 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers6 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership3 Sep
  • 144Davis J. E.1 Sep
  • 4Statement of changes in beneficial ownership31 Aug
  • 144PREVOZNIK MICHAEL E28 Aug
  • SC 13G/AQUEST DIAGNOSTICS INC14 Aug
  • 4Statement of changes in beneficial ownership29 Jul
  • 144DELANEY MARK E28 Jul

News

  • PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records23 Oct
  • Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach23 Oct
  • Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term23 Oct
  • DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market22 Oct
  • What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call22 Oct
  • Quest Diagnostics: 3 Key Takeaways for Long-Term Investors22 Oct
  • Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript22 Oct
  • Quest Diagnostics Bumps Guidance While Managing Quanum System Breach22 Oct
  • Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates22 Oct
  • Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 202622 Oct
  • Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option20 Oct
  • A new at-home HPV test kit is going national through Quest Diagnostics20 Oct
  • Current Screening Thresholds May Miss Half of Patients with Primary Aldosterone, a Leading Cause of Severe High Blood Pressure, Finds Study in Hypertension19 Oct
  • Critical Review: Quest Diagnostics (NYSE:DGX) & Cigna Group (NYSE:CI)18 Oct
  • Dividend Champion, Contender, And Challenger Highlights: Week Of October 1816 Oct
  • Analyzing Mangoceuticals (NASDAQ:MGRX) & Quest Diagnostics (NYSE:DGX)16 Oct
  • Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings14 Oct
  • Here's Why Quest Diagnostics (DGX) is a Strong Value Stock9 Oct
  • Quest Diagnostics Incorporated $DGX Stock Holdings Lifted by Eastern Bank5 Oct
  • Dividend Champion, Contender, And Challenger Highlights: Week October 42 Oct

Mentions in Filings

  • … if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, operating results or financial condition, except as follows: We served <strong>Quest Diagnostics</strong> (“**Quest**”) with a notice of breach in February 2025, stating that Quest failed to obtain approval to perform testing in New York State per agreements we previously entered into with Quest (the “**Quest Agreements* …
    Chemomab Therapeutics Ltd.Quest Diagnostics Inc·S-4/A - Registration statement (business combination, amendment)·Q4 26·19 Oct
  • … irman Larry Venturelli, 65 Director since 2016 CORPORATE FINANCE AND M&A EXPERTISE Robert Hagemann, 69 Independent Director Director since 2014 A\*, N Former SVP, Chief Financial Officer, and Corporate Controller of <strong>Quest Diagnostics</strong> SENIOR EXECUTIVE AND OPERATIONS EXPERTISE Alessandro Maselli, 54 Independent Director Director since 2025 C Director, President and Chief Executive Officer of Catalent Pharma Solutions SENIOR EXECUTVIVE AND FINANCE E …
    GRAPHIC PACKAGING HOLDING COQuest Diagnostics Inc·EX-99.1 - 8-K - Other Events·Q3 26·28 Sep
  • … if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, operating results or financial condition, except as follows: We served <strong>Quest Diagnostics</strong> (“**Quest**”) with a notice of breach in February 2025, stating that Quest failed to obtain approval to perform testing in New York State per agreements we previously entered into with Quest (the “**Quest Agreements* …
    Chemomab Therapeutics Ltd.Quest Diagnostics Inc·S-4 - Registration statement (business combination)·Q3 26·25 Sep
  • … through 2033 3.5x expansion $153M in 2024 to ~$530M by 2033 Growth driven by FDA-cleared IVDs replacing PET and CSF testing, and by amyloid-therapy eligibility screening Source: Grand View Research, Alzheimer’s Disease Diagnostics / blood-based biomarker market (2026–2033), 2025. Regulatory milestones: FDA, Fujirebio, Roche, C2N Diagnostics, Beckman Coulter, Labcorp and <strong>Quest Diagnostics</strong> announcements. 2030 and 2033 values are forecasts. 25 ---
    Acumen Pharmaceuticals, Inc.Quest Diagnostics Inc·EX-99.1 - 8-K - Regulation FD Disclosure·Q3 26·16 Sep
  • … | Naveris, Inc. | CareDx, Inc. | | December 5, 2025 | Foresight Diagnostics Inc. | Natera, Inc. | | November 20, 2025 | Exact Sciences Corporation | Abbott Laboratories | | April 27, 2023 | Haystack Oncology, Inc. | <strong>Quest Diagnostics</strong> Inc. | | November 3, 2022 | Immucor, Inc. | Werfen, S.A. | | October 31, 2022 | The Binding Site Group | Thermo Fisher Scientific Inc. | | December 23, 2021 | Personal Genome Diagnostics Inc. | Labcorp Holdings, Inc. …
    Personalis, Inc.Quest Diagnostics Inc·DEFM14A - Definitive proxy statement (merger)·Q4 26·21 Oct
  • … | Naveris, Inc. | CareDx, Inc. | | December 5, 2025 | Foresight Diagnostics Inc. | Natera, Inc. | | November 20, 2025 | Exact Sciences Corporation | Abbott Laboratories | | April 27, 2023 | Haystack Oncology, Inc. | <strong>Quest Diagnostics</strong> Inc. | | November 3, 2022 | Immucor, Inc. | Werfen, S.A. | | October 31, 2022 | The Binding Site Group | Thermo Fisher Scientific Inc. | | December 23, 2021 | Personal Genome Diagnostics Inc. | Labcorp Holdings, Inc. …
    Tempus AI, Inc.Quest Diagnostics Inc·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·21 Oct

Key Stats

Trading

Px/Chg 1D$0.00 / +0.00%
52 Wk H$0.00
52 Wk L$0.00
Avg Volume0.00
Beta0.00
Mkt Cap0.00

Float

0
Short Float0.00%
Days to Cover0.00
Stock Repurchased$0.00

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgApr '23Apr '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings50.3617.2917.9322.0392.90101.66
Price / Sales4.441.661.651.948.118.85
Price / Book Value2.942.782.432.833.173.48
Price / Free Cash Flow56.3212.4517.7221.1174.13156.21
ENTERPRISE VALUE METRICS
Enterprise Value25,765.020,870.220,233.425,841.229,374.432,505.7
Enterprise Value / Sales5.722.112.192.6210.4711.23
Enterprise Value / EBITDA33.1011.4711.6813.6453.8074.90
Enterprise Value / EBIT40.8615.0915.6518.4473.2581.88

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue56.8%10,788.09,883.09,252.09,872.011,035.0
Gross Income-4.4%4,209.03,433.03,069.03,244.03,523.0
EBITDA-8.7%3,159.01,820.01,732.01,894.02,194.0
EBIT-12.3%2,751.01,383.01,293.01,401.01,624.0
Net Income-16%1,995.0946.0854.0871.0992.0
EPS (Diluted)-13.4%15.537.987.527.698.75
BALANCE SHEET
Cash & ST Inv-16.7%872.0315.0686.0549.0420.0
Total Assets4.5%13,611.012,837.014,022.016,153.016,225.0
Total Liabilities6.1%7,049.06,830.07,604.09,257.08,939.0
Total Shareholder Equity2.7%6,444.05,893.06,307.06,778.07,170.0
CASH FLOW
Net Operating Cash Flow-4.1%2,233.01,718.01,272.01,334.01,886.0
Cap Ex6.9%-403.0-404.0-408.0-425.0-527.0
Free Cash Flow-7.2%1,830.01,314.0864.0909.01,359.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)242.08
Basic Shares110.37
Market Cap26,719.1
Diluted Shares112.00
Fully Diluted Shares Outstanding112.00
Fully Diluted Market Cap27,113.0
+Consolidated Debt6,980.0
−In-the-Money Convertible Debt—
+Capital Leases574.0
+Operating Leases—
−Cash & Equivalents-393.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest300.0
+Pension Liabilities—
Enterprise Value33,606.1

Segment data

Revenue

by Products and services

  • Diagnostic Information Services Business100%

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US